Cisplatin and Radiation Therapy in Treating Patients with Stage II-III Triple Negative Breast Cancer

Inclusion Criteria

• Primary tumor must be triple negative breast cancer (i.e., the invasive tumor must be estrogen receptor [ER]-negative and progesterone receptor [PR]-negative, or stain < 10% by immunohistochemistry [IHC]; the invasive tumor must be HER2-negative, defined as 0 or 1+ by IHC or fluorescent in situ hybridization [FISH] < 2.0)
• Breast-conserving surgery with surgical excision of all gross disease with negative surgical margins (with the exception of a positive margin at skin and/or fascia where no more breast tissue can be removed) or mastectomy surgery with no gross residual disease
• Participants undergoing definitive surgery at diagnosis must have pathologic stage II or III disease
• Participants undergoing preoperative systemic therapy must have clinical stage II or III disease at presentation (clinical stage I disease is excluded)
• Participants undergoing preoperative systemic therapy must have residual invasive disease in the breast or axillary lymph nodes at the time of definitive surgery
• Any prior systemic therapy is permitted (except cisplatin or carboplatin)
• Minimum 3-week interval from last chemotherapy administration and last breast surgery to radiation
• Maximum 8-week interval from last chemotherapy administration or last breast surgery (whichever is more recent) to radiation
• Absolute neutrophil count greater than 1500/mm^3
• Platelet count greater than 100,000/mm^3
• Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 2.5 times upper limit of normal
• Bilirubin =< 1.5 mg/dl
• Glomerular filtration rate (GFR) >= 60 ml/min
• Negative urine pregnancy test within 2 weeks of registration for women of child-bearing potential; women of child-bearing potential must have a documented negative pregnancy test and agree to use adequate contraception throughout the study period
• Ability and willingness to sign written informed consent
• Patients with tumors of two different subtypes will be eligible provided that the triple negative tumor otherwise meets eligibility requirements, and the non-triple negative tumor is < 1.0 cm in size
• Patients with inflammatory breast cancer are eligible for the escalation phase of the mastectomy cohort

Exclusion Criteria

• Prior radiation therapy to the breast or ipsilateral regional nodes not allowed (a history of radiation therapy to other sites is permissible)
• Ongoing therapy with other investigational agents
• Hormonal therapy (tamoxifen, an aromatase inhibitor, or Lupron) is not permitted during radiation or during the subsequent 4 weeks (the entire dose-limiting toxicity [DLT] window)
• Unresolved toxicity from other agents; participants with unresolved or unstable Common Toxicity Criteria Adverse Event version 4 (CTCAE v4) grade 2 or greater toxicity from prior administration of another anti-cancer treatment are not eligible
• Significant comorbidity: ineligible participants include those with clinically significant and uncontrolled major cardiac, respiratory, renal hepatic, gastrointestinal, hematologic, or neurologic/psychiatric disease or disorder, including, but not limited to: active or uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmias, or any other illness or condition that could exacerbate potential toxicities, confound safety assessment or limit compliance with study requirements
• Pregnant women are excluded from this study
• Pathologic complete response following preoperative chemotherapy
• Participants with biopsy proven metastatic disease (M1)
• Peripheral neuropathy greater than grade 1
• Hearing loss greater than grade 1
• Inflammatory breast cancer patients are ineligible, except in the escalation phase of the mastectomy cohort